Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology

Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ‐based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof‐of‐concept of network pharmacology.